AmirAli Talasaz

Co-founder and co-CEO, Guardant Health

Appears in 1 story

Born: August 3, 1979

Education: Stanford University

Last updated Nov 1, 2026

Stories

FDA approves Guardant360 Liquid CDx with 100x larger genomic panel

New Capabilities

As of May 2026: Leading R&D on the Smart Platform behind the new test

For most patients with advanced cancer, picking the right targeted drug still starts with a tissue biopsy. On May 20, the FDA approved a blood test that reads 100 times more of the tumor's DNA than the previous version.

Updated May 20